Xencor (NASDAQ:XNCR) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened

Shares of Xencor, Inc. (NASDAQ:XNCR) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $12.49 and traded as low as $11.75. Xencor shares last traded at $12.22, with a volume of 415,474 shares.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Truist Financial assumed coverage on shares of Xencor in a report on Monday, November 24th. They set a “buy” rating and a $29.00 target price on the stock. Barclays upped their price target on shares of Xencor from $23.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Royal Bank Of Canada raised their price objective on Xencor from $18.00 to $19.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Cantor Fitzgerald boosted their target price on Xencor from $40.00 to $42.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Finally, JPMorgan Chase & Co. dropped their target price on Xencor from $20.00 to $18.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.88.

Xencor Stock Down 1.2%

The company has a market capitalization of $872.63 million, a PE ratio of -6.90 and a beta of 0.98. The stock’s fifty day moving average price is $14.32 and its two-hundred day moving average price is $12.49.

Insider Activity at Xencor

In related news, CEO Bassil I. Dahiyat sold 114,377 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $15.71, for a total value of $1,796,862.67. Following the completion of the sale, the chief executive officer owned 466,635 shares of the company’s stock, valued at $7,330,835.85. This trade represents a 19.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP John R. Desjarlais sold 73,367 shares of Xencor stock in a transaction on Friday, December 19th. The shares were sold at an average price of $15.72, for a total transaction of $1,153,329.24. Following the completion of the sale, the vice president owned 236,574 shares in the company, valued at approximately $3,718,943.28. This trade represents a 23.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 4.76% of the company’s stock.

Institutional Investors Weigh In On Xencor

Several institutional investors and hedge funds have recently modified their holdings of XNCR. Hantz Financial Services Inc. increased its position in shares of Xencor by 209.1% during the third quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 2,156 shares during the period. GAMMA Investing LLC boosted its position in Xencor by 77.1% during the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 1,449 shares in the last quarter. Farther Finance Advisors LLC purchased a new position in shares of Xencor during the 3rd quarter worth approximately $44,000. Federated Hermes Inc. raised its position in shares of Xencor by 114.3% in the 3rd quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 2,105 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Xencor by 85.5% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,260 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 2,424 shares during the period.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.